A detailed history of Geode Capital Management, LLC transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Geode Capital Management, LLC holds 117,909 shares of ADAP stock, worth $115,550. This represents 0.0% of its overall portfolio holdings.

Number of Shares
117,909
Previous 117,909 -0.0%
Holding current value
$115,550
Previous $93,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$0.9 - $1.51 $10,799 - $18,118
11,999 Added 11.33%
117,909 $108,000
Q4 2022

Feb 13, 2023

BUY
$1.05 - $2.53 $34,798 - $83,846
33,141 Added 45.54%
105,910 $154,000
Q1 2021

May 12, 2021

BUY
$4.9 - $6.83 $115,546 - $161,058
23,581 Added 47.94%
72,769 $386,000
Q4 2020

Feb 12, 2021

SELL
$4.0 - $9.2 $245,868 - $565,496
-61,467 Reduced 55.55%
49,188 $265,000
Q3 2020

Nov 13, 2020

BUY
$7.66 - $10.78 $380,724 - $535,798
49,703 Added 81.54%
110,655 $883,000
Q2 2020

Aug 13, 2020

BUY
$2.58 - $12.1 $24,672 - $115,712
9,563 Added 18.61%
60,952 $610,000
Q1 2020

May 14, 2020

SELL
$1.2 - $4.52 $55,941 - $210,713
-46,618 Reduced 47.57%
51,389 $139,000
Q4 2019

Feb 13, 2020

BUY
$0.72 - $1.43 $24,485 - $48,630
34,007 Added 53.14%
98,007 $117,000
Q1 2019

May 14, 2019

BUY
$3.63 - $6.06 $89,849 - $149,997
24,752 Added 63.07%
64,000 $275,000
Q4 2018

Feb 13, 2019

SELL
$3.76 - $14.16 $1,530 - $5,763
-407 Reduced 1.03%
39,248 $225,000
Q3 2018

Nov 13, 2018

SELL
$8.27 - $13.56 $12,256 - $20,095
-1,482 Reduced 3.6%
39,655 $537,000
Q2 2018

Aug 14, 2018

SELL
$10.42 - $13.74 $21,611 - $28,496
-2,074 Reduced 4.8%
41,137 $487,000
Q1 2018

May 15, 2018

BUY
$7.1 - $11.56 $103,262 - $168,128
14,544 Added 50.73%
43,211 $485,000
Q4 2017

Feb 13, 2018

BUY
$6.68 - $8.74 $414 - $541
62 Added 0.22%
28,667 $191,000
Q2 2017

Aug 14, 2017

BUY
N/A
28,605
28,605 $128,000

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $160M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.